Biologic Treatment in Combination with Lifestyle Intervention in Moderate to Severe Plaque Psoriasis and Concomitant Metabolic Syndrome: Rationale and Methodology of the METABOLyx Randomized Controlled Clinical Trial
Inflammatory diseases including psoriasis are associated with metabolic and cardiovascular comorbidities, including obesity and metabolic syndrome. Obesity is associated with greater psoriasis disease severity and reduced response to treatment. Therefore, targeting metabolic comorbidities could impr...
Main Authors: | Andreas Pinter, Peter Schwarz, Sascha Gerdes, Jan C. Simon, Anja Saalbach, James Rush, Nima Melzer, Thomas Kramps, Benjamin Häberle, Maximilian Reinhardt |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/13/9/3015 |
Similar Items
-
Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
by: Andreas Pinter, et al.
Published: (2020-11-01) -
ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients
by: Peter E. H. Schwarz, et al.
Published: (2019-07-01) -
The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022-02-01) -
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01) -
Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01)